Answers are grounded in this paper and cite their sources.
Recent inventions have unveiled two complementary therapeutic strategies: cyclic peptides that trigger the lysosomal degradation of the epidermal growth factor receptor (EGFR), and soluble peptide-MHC constructs that suppress autoreactive T-cell receptors in multiple sclerosis. Together, these innovations highlight emerging frameworks for precision control of receptor signaling and adaptive immunity using structurally defined peptide modulators.
No takes yet. Share an insight, caveat, or question.
Renner et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: